Streetbeat News

ELV

Elevance Health Inc.

https://www.elevancehealth.com

Industry

Medical - Healthcare Plans

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Open

405.00

Mkt cap

93B

Volume

2.6M

High

408.58

P/E Ratio

14.58

52-wk high

567.26

Low

398.69

Div yield

0.02

52-wk low

397.98

Elevance Health (ELV) has seen a 20% decline in its stock price over the past three months due to challenges like higher benefit costs, increased debt, and member attrition in its Medicaid business. These issues are causing investor concerns.

Portfolio Pulse from

November 12, 2024 | 7:15 pm

Johnson Fistel, LLP is investigating Elevance Health, Inc. for potential securities law violations related to misrepresentation or failure to disclose adverse information, which may have led to investor losses.

Portfolio Pulse from

November 07, 2024 | 10:00 pm

Elevance Health (NYSE:ELV) has outperformed the market over the past 15 years with an average annual return of 15.1%, surpassing the market by 2.99% annually. A $100 investment in ELV 15 years ago would now be worth $850.24.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 8:06 pm

Morgan Stanley has maintained an Overweight rating on Elevance Health but has lowered the price target from $643 to $551.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:02 pm

Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health but lowers the price target from $622 to $501.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 4:22 pm

Analysts have provided mixed evaluations for Elevance Health (NYSE:ELV) over the past quarter, with a trend towards lowering price targets. The average 12-month price target is now $559.91, down 7.03% from the previous $602.27. Despite some positive financial metrics, such as ROE and ROA, Elevance Health faces challenges with net margin and revenue growth compared to industry peers.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 8:00 pm

TD Cowen analyst Ryan Langston maintains a Buy rating on Elevance Health but lowers the price target from $589 to $484.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 12:45 pm

Several large-cap stocks experienced significant declines last week, including NIO, ASML, and CVS Health. Factors such as China's export data, earnings reports, and guidance revisions contributed to these losses.

Portfolio Pulse from Lekha Gupta

October 20, 2024 | 8:04 pm

Elevance Health, CVS Health, and UnitedHealth Group are facing increased medical costs due to the end of a COVID-19 policy that maintained continuous Medicaid enrollment. This has led to lowered profit forecasts and earnings outlooks for these companies.

Portfolio Pulse from Erica Kollmann

October 18, 2024 | 4:09 pm

Elevance Health Inc. (NYSE:ELV) reported weaker-than-expected Q3 earnings, with a 21% drop in profit and adjusted EPS missing consensus estimates. Despite revenue growth, the company lowered its full-year guidance. Analysts have cut their price targets for ELV, reflecting concerns over its performance.

Portfolio Pulse from Avi Kapoor

October 18, 2024 | 3:54 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.